EVG.L Regulatory News (EVG)

EVG.L Information

There is currently no data for EVG

REMOVE ADS

Temporary Suspension Evolution Group PLC

21 Dec 2011 16:30

RNS Number : 4500U

Official List

21 December 2011

NOTICE OF TEMPORARY SUSPENSION OF LISTING FROM THE OFFICIAL LIST

21/12/2011 4:30PM

TEMPORARY SUSPENSION

Evolution Group PLC

The Financial Services Authority ("the FSA") temporarily suspends the securities set out below from the Official List effective from 21/12/2011 4:30 PM at the request of the company pending an announcement :

Ordinary Shares of 1p each

fully paid

Premium Equity Commercial Companies

(GB0030221864)

This notice has been issued by Listing Applications - 0207 066 8333 Option 3.

This information is provided by RNS

The company news service from the London Stock Exchange

END

SUSFEWFIFFFSEIE

Date		Source	Headline
10th Oct 2022	11:05 am	RNS	Second Price Monitoring Extn
10th Oct 2022	11:00 am	RNS	Price Monitoring Extension
10th Oct 2022	7:00 am	RNS	SFX-01 licensing deal for up to $160.5m
29th Sep 2022	7:00 am	RNS	Regulatory approval for healthy volunteer study
22nd Jul 2022	7:00 am	RNS	Result of AGM
14th Jul 2022	12:43 pm	RNS	Investor Presentation
6th Jul 2022	12:25 pm	RNS	Notice of AGM
13th Jun 2022	7:00 am	RNS	Collaboration with University of Michigan
8th Jun 2022	7:00 am	RNS	Full Year Results
7th Jun 2022	7:00 am	RNS	Notice of Results
25th May 2022	7:00 am	RNS	Collaboration with Università Sapienza di Roma
29th Apr 2022	2:39 pm	RNS	Holding(s) in Company
15th Mar 2022	2:05 pm	RNS	Second Price Monitoring Extn
15th Mar 2022	2:00 pm	RNS	Price Monitoring Extension
7th Mar 2022	7:00 am	RNS	Manchester Breast Centre collaboration expanded
18th Jan 2022	7:00 am	RNS	Option over new sulforaphane analogues
11th Jan 2022	7:00 am	RNS	Progress with UK and US regulators for 2022 trials
30th Dec 2021	11:35 am	RNS	Holding(s) in Company
8th Dec 2021	2:08 pm	RNS	Grant of Options
7th Dec 2021	7:00 am	RNS	Half-year Report
23rd Nov 2021	7:00 am	RNS	Notice of Results
10th Nov 2021	7:00 am	RNS	Publication of data on SFX-01 in glioblastoma
19th Oct 2021	2:39 pm	RNS	Holding(s) in Company
20th Sep 2021	7:00 am	RNS	Publication of data in glioblastoma cells
2nd Sep 2021	2:32 pm	RNS	Holding(s) in Company
2nd Sep 2021	2:06 pm	RNS	Second Price Monitoring Extn
2nd Sep 2021	2:00 pm	RNS	Price Monitoring Extension
2nd Sep 2021	11:05 am	RNS	Second Price Monitoring Extn
2nd Sep 2021	11:01 am	RNS	Glioma Orphan Drug designation granted by FDA
2nd Sep 2021	11:00 am	RNS	Price Monitoring Extension
25th Aug 2021	4:42 pm	RNS	Holding(s) in Company
24th Aug 2021	4:41 pm	RNS	Second Price Monitoring Extn
24th Aug 2021	4:36 pm	RNS	Price Monitoring Extension
9th Aug 2021	5:06 pm	RNS	Holding(s) in Company
20th Jul 2021	11:57 am	RNS	Holding(s) in Company
16th Jul 2021	1:50 pm	RNS	Holding(s) in Company
14th Jul 2021	10:23 am	RNS	Holding(s) in Company
13th Jul 2021	5:02 pm	RNS	Result of AGM and Business Update
13th Jul 2021	3:55 pm	RNS	Holding(s) in Company
13th Jul 2021	7:00 am	RNS	Early data for SFX-01 in leukaemia cell lines
13th Jul 2021	7:00 am	RNS	Glioma Orphan Drug application submitted to US FDA
9th Jul 2021	11:05 am	RNS	Second Price Monitoring Extn
9th Jul 2021	11:00 am	RNS	Price Monitoring Extension
9th Jul 2021	7:00 am	RNS	Interim Safety and Futility Analysis - STAR trial
18th Jun 2021	7:00 am	RNS	Posting of Annual Report and Notice of AGM
15th Jun 2021	7:00 am	RNS	Final Results
14th Jun 2021	7:00 am	RNS	Progress on metastatic breast cancer programme
14th Jun 2021	7:00 am	RNS	Progress with Glioma/Glioblastoma programme
26th Apr 2021	7:00 am	RNS	Appointment of Chief Medical Officer
7th Apr 2021	7:00 am	RNS	Publication on sulforaphane in COVID-19

Latest Share Chat

EVG.L Regulatory News (EVG)

Temporary Suspension Evolution Group PLC

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending